Creaven Pj - Concepedia

Author

Creaven Pj

Roswell Park Comprehensive Cancer Center

Also Known As

Creaven Pj, P J Creaven, P. Creaven, PJ CREAVEN, PJ Creaven

Publications

681

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center

About

Creaven Pj is an author at Roswell Park Comprehensive Cancer Center specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	380
2	Metabolism	2	2	103
3	Health Sciences	1	1	62
4	Biochemistry	1	1	15
5	Immunology	1	1	46

Creaven Pj

Publications

648

Citations

H-Index

Page 1

	Year	Citations
Treatment of acute nonlymphocytic leukemia: use of anthracycline- cytosine arabinoside induction therapy and comparison of two maintenance regimens HD Preisler, Youcef M. Rustum, Henderson Es, Blood	1979	150
Treatment of acute nonlymphocytic leukemia: use of anthracycline- cytosine arabinoside induction therapy and comparison of two maintenance regimens HD Preisler, Youcef M. Rustum, Henderson Es, Blood	1979	118
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Creaven Pj, Allen Lm, Franco M. Muggia PubMed Therapeutic Drug MonitoringPharmacology5-Day CourseToxicologyPharmacotherapy	1972	67
Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). Creaven Pj, Stefan Madajewicz, Lakshmi Pendyala, PubMed Serum CreatinineOncologyClinical TherapeuticMetronomic TherapyPharmacology	1983	62
Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Allen Lm, Creaven Pj, Nelson Rl PubMed PharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmacokineticsMolecular PharmacologyPharmacological Study	1976	53
Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Leme Pr, Creaven Pj, Allen Lm, PubMed Pharmacokinetic ModelingPharmacological StudyMedicineClinical PharmacologyToxicology	1975	50
Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. Creaven Pj, Cowens Jw, Brenner De, PubMed Lipid PreparationAdvanced CancerDrug TargetingOncologyInitial Clinical Trial	1990	46
The clinical toxicity of anticancer drugs and its prediction. Creaven Pj, Enrico Mihich PubMed OncologyMedicineClinical ToxicityPharmacotherapyAnti-cancer Agent	1977	30
Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). Creaven Pj, Newman Sj, Selawry Os, PubMed Clinical TherapeuticPharmacologyWeekly AdministrationPharmacotherapyMedicine	1975	23
Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol Nj, Creaven Pj, Petrelli Nj PubMed OncologyBiochemical ModulationGastrointestinal OncologyMedicinePharmacology	1995	22

Page 1